This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Prostate cancer is the most common cancer in men—in 2013, it affected more than 1 million men across the world. The cancer does not behave the same way in every patient, and doctors have long faced a difficult balancing act between identifying patients who will benefit from more intensive treatment and those who may do just as well without it. Treating someone more aggressively than necessary is associated with increased side effects and poorer quality of life.

At a major cancer conference in Madrid, a team from University College London unveiled the latest findings from their STAMPEDE clinical trial, which has shown that adding the hormone therapy abiraterone to the standard treatment for men with high-risk, localized prostate cancer could halve the risk of death from the disease and slow overall progression.

However, not all trials have shown that adding extra hormonal therapies to high-risk prostate cancer is beneficial, and in their new study, the researchers wanted to know whether an additional test—the Decipher tissue-based molecular test—could be used to determine which patients would benefit most from more intensive treatment. Side effects of abiraterone include fatigue.

The UCL team analyzed Decipher scores from two datasets—real-world data of 27,607 (of which 5,956 were analyzed for outcomes) and 401 men with non-metastatic prostate cancer randomized within the STAMPEDE abiraterone trial.

38.

Source link